Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer

Author(s): Antill, Y; Buchanan, DD; Scott, CL;
Details: Publication Year 2022-03-15,Volume 128,Issue #6,Page 1157-1161
Journal Title: Cancer
Publication Type: Commentary
Abstract: Endometrial cancer is common, and a subset recurs and requires additional treatment. Some of these are recognized as being susceptible to immune therapies and are said to have mismatch repair deficiency (dMMR). However, this clinical trial highlights which cases are more likely to respond well: those containing mutations in genes known as Lynch genes and also some with mutations in POLE/POLD1 ("ultra-hypermutation" genes). In contrast, the majority of dMMR endometrial cancers have silencing or DNA methylation of one of these genes, MLH1, and do not seem to be as responsive to single-agent immune therapy. The availability of combination therapies may be important to consider for these women.
Keywords: *Colorectal Neoplasms, Hereditary Nonpolyposis/genetics; DNA Mismatch Repair/genetics; *Endometrial Neoplasms/drug therapy/genetics; Female; Humans; Immune Checkpoint Inhibitors/therapeutic use; MutL Protein Homolog 1/genetics; Neoplasm Recurrence, Local/drug therapy
Department(s): Medical Oncology
PubMed ID: 34875102
Publisher's Version: https://doi.org/10.1002/cncr.34024
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-09-26 05:45:09

Last Modified: 2024-09-26 05:48:04